Objective: To elaborate recommendations for the treatment of rheumatoid arthritis in Brazil. Method: Literature review with articles' selection based on evidence and the expert opinion of the Rheumatoid Arthritis Committee of the Brazilian Society of Rheumatology. Results and conclusions: 1) The therapeutic decision should be shared with the patient; 2) immediately after the diagnosis, a disease-modifying antirheumatic drug (DMARD) should be prescribed, and the treatment adjusted to achieve remission; 3) treatment should be conducted by a rheumatologist; 4) the initial treatment includes synthetic DMARDs; 5) methotrexate is the drug of choice; 6) patients who fail to respond after two schedules of synthetic DMARDs should be assessed for the use of biologic DMARDs; 7) exceptionally, biologic DMARDs can be considered earlier; 8) anti-TNF agents are preferentially recommended as the initial biologic therapy; 9) after therapeutic failure of a first biologic DMARD, other biologics can be used; 10) cyclophosphamide and azathioprine can be used in severe extra-articular manifestations; 11) oral corticoid is recommended at low doses and for short periods of time; 12) non-steroidal anti-inflammatory drugs should always be prescribed in association with a DMARD; 13) clinical assessments should be performed on a monthly basis at the beginning of treatment; 14) physical therapy, rehabilitation, and occupational therapy are indicated; 15) surgical treatment is recommended to correct sequelae; 16) alternative therapy does not replace traditional therapy; 17) family planning is recommended; 18) the active search and management of comorbidities are recommended; 19) the patient's vaccination status should be recorded and updated; 20) endemic-epidemic transmissible diseases should be investigated and treated. © 2012 Elsevier Editora Ltda. All rights reserved.522135174Alamanos, Y., Voulgari, P.V., Drosos, A.A., Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: A systematic review (2006) Semin Arthritis Rheum, 36 (3), pp. 182-188Marques-Neto, J.F., Gonlves, E.T., Langen, L.F.O.B., Cunha, M.F.L., Radominski, S., Oliveira, S.M., Multicentric study of the prevalence of adult rheumatoid arthritis in Brazilian population samples (1993) Rev Bras Reumatol, 33, pp. 169-173Verstappen, S.M., van Albada-Kuipers, G.A., Bijlsma, J.W., Blaauw, A.A., Schenk, Y., Haanen, H.C., A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up (2005) Ann Rheum Dis, 64 (1), pp. 38-43Chehata, J.C., Hassell, A.B., Clarke, S.A., Mattey, D.L., Jones, M.A., Jones, P.W., Mortality in rheumatoid arthritis: Relationship to single and composite measures of disease activity (2001) Rheumatology, 40 (4), pp. 447-452da Mota, L.M., Cruz, B.A., Brenol, C.V., Pereira, I.A., Fronza, L.S., Bertolo, M.B., Consensus of the Brazilian Society of Rheumatology for diagnosis and early assessment of rheumatoid arthritis (2011) Rev Bras Reumatol, 51 (3), pp. 199-219de Azevedo, A.B., Ferraz, M.B., Ciconelli, R.M., Indirect costs of rheumatoid arthritis in Brazil (2008) Value Health, 11 (5), pp. 869-877McInnes, I.B., O'Dell, J.R., State-of-the-art: Rheumatoid arthritis (2010) Ann Rheum Dis, 69 (11), pp. 1898-1906Klarenbeek, N.B., Kerstens, P.J., Huizinga, T.W., Dijkmans, B.A., Allaart, C.F., Recent advances in the management of rheumatoid arthritis (2010) BMJ, 341, pp. c6942Abourazzak, F., El-Mansouri, L., Huchet, D., Lozac'hmeur, R., Hajjaj-Hassouni, N., Ingels, A., A Long-term effects of therapeutic education for patients with rheumatoid arthritis (2009) Joint Bone Spine, 76 (6), pp. 648-653Lovisi, N.B.E., Jennings, F., Barros, O.C., Silva, P.G., Natour, J., Evaluation of the Efficacy of an educational program for rheumatoid arthritis patients (2009) Clin Exp Rheumatol, 27 (1), pp. 28-34Masiero, S., Boniolo, A., Wassermann, L., Machiedo, H., Volante, D., Punzi, L., Effects of an educational-behavioral joint protection program on people with moderate to severe rheumatoid arthritis: A randomized controlled trial (2007) Clin Rheumatol, 26 (12), pp. 2043-2050Osiri, M., Shea, B., Robinson, V., Suarez-Almazor, M., Strand, V., Tugwell, P., Leflunomide for treating rheumatoid arthritis (2003) Cochrane Database Syst Rev, 5 (1). , CD002047Hamilton, J., McInnes, I.B., Thomson, E.A., Porter, D., Hunter, J.A., Madhok, R., Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area (2001) Ann Rheum Dis, 60 (6), pp. 566-572van der Heijde, D.M., van Riel, P.L., Nuver-Zwart, I.H., van de Putte, L.B., Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up (1990) Lancet, 335 (8688), pp. 539-553Svensson, B., Boonen, A., Albertsson, K., van der Heijde, D., Keller, C., Hafstr, I., Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial (2005) Arthritis Rheum, 52 (11), pp. 3360-7054Kremer, J.M., Genovese, M.C., Cannon, G.W., Caldwell, J.R., Cush, J.J., Furst, D.E., Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate (2002) Ann Intern Med, 137 (9), pp. 726-733. , A randomized, double-blind, placebo-controlled trialTitton, D.C., Silveira, I.G., Louzada-Junior, P., Hayata, A.L., Carvalho, H.M., Ranza, R., Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results (2011) Rev Bras Reumatol, 51 (2), pp. 152-160Salliot, C., Finckh, A., Katchamart, W., Lu, Y., Sun, Y., Bombardier, C., Indirect comparisons of the Efficacy of biological anti-rheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying anti-rheumatic drugs or to an anti-tumour necrosis factor agent: A meta-analysis (2011) Ann Rheum Dis, 70 (2), pp. 266-271Malottki, K., Barton, P., Tsourapas, A., Uthman, A.O., Liu, Z., Routh, K., Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: A systematic review and economic evaluation (2011) Health Technol Assess, 15 (14), pp. 1-278O'Mahony, R., Richards, A., Deighton, C., Scott, D., Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A systematic review and meta-analysis (2010) Ann Rheum Dis, 69 (10), pp. 1823-1826Grigor, C., Capell, H., Stirling, A., McMahon, A.D., Lock, P., Vallance, R., Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial (2004) Lancet, 364 (9430), pp. 263-269Niedermann, K., de Bie, R.A., Kubli, R., Ciurea, A., Steurer-Stey, C., Villiger, P.M., Effectiveness of individual resource-oriented joint protection education in people with rheumatoid arthritis (2001) Patient Educ Couns, 82 (1), pp. 42-48. , A randomized controlled trialDeighton, C., Omahony, R., Tosh, J., Turner, C., Rudolf, M., Management of rheumatoid arthritis: Summary of NICE guidance (2009) BMJ, 338, pp. b702. , Guideline Development GroupVliet Vlieland, T.P., Rehabilitation of people with rheumatoid arthritis (2003) Best Pract Res Clin Rheumatol, 17 (5), pp. 847-861Garber, C.E., Blissmer, B., Deschenes, M.R., Franklin, B.A., Lamonte, M.J., Lee, I.M., Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: Guidance for prescribing exercise (2011) Med Sci Sports Exerc, 43 (7), pp. 1334-1359. , American College of Sports Medicine. American College of Sports Medicine position standBaillet, A., Payraud, E., Niderprim, V.-A., Nissen, M.J., Allenet, B., Franis, P., A dynamic exercise program to improve patients' disability in rheumatoid arthritis: A prospective randomized controlled trial (2009) Rheumatology, 48 (4), pp. 10-415de Jong, Z., Munneke, M., Zwinderman, A.H., Kroon, H.M., Jansen, A., Ronday, K.H., Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial (2003) Arthritis Rheum, 48 (9), pp. 2415-2424Munneke, M., de Jong, Z., Zwinderman, A.H., Ronday, H.K., van Schaardenburg, D., Dijkmans, B.A., Effect of a high-intensity weight-bearing exercise program on radiologic damage progression of the large joints in subgroups of patients with rheumatoid arthritis (2005) Arthritis Rheum, 53 (3), pp. 410-417Robinson, V., Brosseau, L., Casimiro, L., Judd, M., Shea, B., Wells, G., Thermotherapy for treating rheumatoid arthritis (2002) Cochrane Database Syst Rev, 2. , CD002826Brosseau, L.U., Pelland, L.U., Casimiro, L.Y., Robinson, V.I., Tugwell, P.E., Wells, G.E., Electrical stimulation for the treatment of rheumatoid arthritis (2002) Cochrane Database Syst Rev, 2. , CD003687Brosseau, L., Judd, M.G., Marchand, S., Robinson, V.A., Tugwell, P., Wells, G., Transcutaneous electrical nerve stimulation (TENS) for the treatment of rheumatoid arthritis in the hand (2003) Cochrane Database Syst Rev, 3. , CD004377Brosseau, L., Robinson, V., Wells, G., Debie, R., Gam, A., Harman, K., Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis (2005) Cochrane Database Syst Rev, 4. , CD002049Lineker, S.C., Bell, M.J., Badley, E.M., Evaluation of an inter-professional educational intervention to improve the use of arthritis best practices in primary care (2011) J Rheumatol, 38 (5), pp. 931-937Meireles, S.M., Jones, A., Jennings, F., Suda, A.L., Parizotto, N.A., Natour, J., Assessment of the effectiveness of low-level laser therapy on the hands of patients with rheumatoid arthritis: A randomized doubleblind controlled trial (2010) Clin Rheumatol, 29 (5), pp. 501-509Vliet Vlieland, T.P., van den Ende, C.H., Nonpharmacological treatment of rheumatoid arthritis (2011) Curr Opin Rheumatol, 23 (3), pp. 259-264Hand, C., Law, M., McColl, M.A., Occupational therapy interventions for chronic diseases: A scoping review (2011) Am J Occup Ther, 65 (4), pp. 428-436Vliet Vlieland, T.P., Non-drug care for RA - is the era of evidencebased practice approaching? (2007) Rheumatology, 46 (9), pp. 1397-1404Veehof, M.M., Taal, E., Heijnsdijk-Rouwenhorst, L.M., van de Laar, M.A., Efficacy of wrist working splints in patients with rheumatoid arthritis: A randomized controlled study (2008) Arthritis Rheum, 59 (12), pp. 1698-1704Boonen, A., Matricali, G.A., Verduyckt, J., Taelman, V., Verschueren, P., Sileghem, A., Orthopaedic surgery in patients with rheumatoid arthritis: A shift towards more frequent and earlier non-jointsGuidelines for the management of rheumatoid arthritis: 2002 Update (2002) Arthritis Rheum, 46 (2), pp. 328-346. , American College of Rheumatology Subcommittee on Rheumatoid Arthritis GuidelinesKatchamart, W., Johnson, S., Lin, H.J., Phumethum, V., Salliot, C., Bombardier, C., Predictors for remission in rheumatoid arthritis patients: A systematic review (2010) Arthritis Care Res (Hoboken), 62 (8), pp. 1128-1143Ferraz-Amaro, I., Machín, S., Carmona, L., González-Alvaro, I., Diaz-Gonzáez, F., A prospective analysis from clinical practice (2009) Reumatol Clin, 5 (6), pp. 252-258. , EMECAR study group. Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patientsSolomon, D.H., Rassen, J.A., Glynn, R.J., Lee, J., Levin, R., Schneeweiss, S., The comparative safety of analgesics in older adults with arthriti (2010) Arch Intern Med, 170 (22), pp. 1968-1976. , Erratum in: Arch Intern Med 2011171(5):403Chen, Y.F., Jobanputra, P., Barton, P., Bryan, S., Fry-Smith, A., Harris, G., Cyclooxygenase-2 selective non-steroidal anti-inflamatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: A systematic review and economic evaluation (2008) Health Technol Assess, 12 (11), pp. 1-278van Everdingen, A.A., Jacobs, J.W., van Siewertsz, R.D.R., Bijlsma, J.W., Low-dose prednisone therapy for patients with early rheumatoid arthritis: Clinical Efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial (2002) Ann Intern Med, 136 (1), pp. 1-12Smolen, J.S., Landewé, R., Breedveld, F.C., Dougados, M., Emery, P., Gaujoux-Viala, C., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010) Ann Rheum Dis, 69 (6), pp. 964-975. , Erratum in: Ann Rheum Dis 201170(8):1519Hoes, J.N., Jacobs, J.W., Verstappen, S.M., Bijlsma, J.W., van der Heijden, G.J., Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: A meta-analysis (2009) Ann Rheum Dis, 68 (12), pp. 1833-1838Dernis, E., Ruyssen-Witrand, A., Mouterde, G., Maillefert, J.F., Tebib, J., Cantagrel, A., Use of glucocorticoids in rheumatoid arthritis - pratical modalities of glucocorticoid therapy: Recommendations for clinical practice based on data from the literature and expert opinion (2010) Joint Bone Spine, 77 (5), pp. 451-457Furst, D.E., Pangan, A.L., Harrold, L.R., Chang, H., Reed, G., Kremer, J.M., Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry (2011) Arthritis Care Res (Hoboken), 63 (6), pp. 856-864Lukas, C., Combe, B., Ravaud, P., Sibilia, J., Landew, R., van der Heijde, D., Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the étude et Suivi des polyarthrites indiffencis réentes (study and followup of early undifferentiated polyarthritis) (2011) Arthritis Rheum, 63 (7), pp. 1804-1811Cronstein, B., How does methotrexate suppress inflammation? (2010) Clin Exp Rheumatol, 28 (5 SUPPL 61), pp. S21-S23Pincus, T., Cronstein, B., Braun, J., Methotrexate - the anchor drug - an introduction (2010) Clin Exp Rheumatol, 28 (5 SUPPL 61), pp. S1-S2O'Dell, J.R., Haire, C.E., Erikson, N., Drymalski, W., Palmer, W., Eckhoff, P.J., Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications (1996) N Engl J Med, 334 (20), pp. 1287-1291Pereira, I.A., Cruz, B.A., Xavier, R.M., Pinheiro, G.R.C., Titton, D.C., Giorgi, R.D.N., National recommendations based on scientific evidence and opinions of experts on the use of methotrexate in rheumatic disorders, especially in rheumatoid arthritis: Results of the 3E Initiative from Brazil (2009) Rev Bras Reumatol, 49 (4), pp. 346-361Williams, H.J., Ward, J.R., Dahl, S.L., Clegg, D.O., Willkens, R.F., Oglesby, T., A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis (1988) Arthritis Rheum, 31 (6), pp. 702-713Boers, M., Verhoeven, A.C., Markusse, H.M., van de Laar, M.A., Westhovens, R., van Denderen, J.C., Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis (1997) Lancet, 350 (9074), pp. 309-318. , Erratum in: Lancet 1998351(9097):220Rozman, B., Clinical pharmacokinetics of leflunomide (2002) Clin Pharmacokinet, 41 (6), pp. 421-430Scott, D.L., Smolen, J.S., Kalden, J.R., van de Putte, L.B., Larsen, A., Kvien, T.K., Treatment of active rheumatoid arthritis with leflunomide: Two year follow up of a double blind, placebo controlled trial versus sulfasalazine (2001) Ann Rheum Dis, 60 (10), pp. 913-923. , European Leflunomide Study GroupKalden, J.R., Scott, D.L., Smolen, J.S., Schattenkirchner, M., Rozman, B., Williams, B.D., Improved functional ability in patients with rheumatoid arthritis: Longterm treatment with leflunomide versus sulfasalazina (2001) J Rheumatol, 28 (9), pp. 1983-1991. , European Leflunomide Study GroupClark, P., Casas, E., Tugwell, P., Medina, C., Gheno, C., Tenorio, G., Hydroxychloroquine compared with placebo in rheumatoid arthritis (1993) Ann Intern Med, 119 (11), pp. 1067-1071. , A randomized controlled trialA randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study (1995) Am J Med, 98 (2), pp. 156-168Marmor, M.F., Kellner, U., Lai, T.Y., Lyons, J.S., Mieler, W.F., American Academy of Ophthalmology (2011) Ophthalmology, 118 (2), pp. 415-422. , Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathySuarez-Almazor, M.E., Belseck, E., Shea, B., Homik, J., Wells, G., Tugwell, P., Antimalarials for treating rheumatoid arthritis (2000) Cochrane Database Syst Rev, 4. , CD000959Rau, R., Herborn, G., Menninger, H., Sangha, O., Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold (2002) Rheumatology (Oxford), 41 (2), pp. 196-204. , Extension of a one-year double-blind study in 174 patientsLehman, A.J., Esdaile, J.M., Klinkhoff, A.V., Grant, E., Fitzgerald, A., Canvin, J., A 48-week, randomized, doubleblind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: Results of the METGO study (2005) Arthritis Rheum, 52 (5), pp. 1360-1370. , METGO Study GroupCaporali, R., Conti, F., Alivernini, S., Atzeni, F., Seriolo, B., Cutolo, M., Recommendations for the use of biologic therapy in rheumatoid arthritis: Update from the Italian Society for Rheumatology I (2011) Efficacy. Clin Exp Rheumatol, 29 (3 SUPPL 66), pp. S7-S14Favalli, E.G., Caporali, R., Sinigaglia, L., Pipitone, N., Miniati, I., Montecucco, C., Recommendations for the use of biologic therapy in rheumatoid arthritis: Update from the Italian Society for Rheumatology II (2011) Safety. Clin Exp Rheumatol, 29 (3 SUPPL 66), pp. S15-S27http://portal.anvisa.gov.br/wps/portal/anvisa, Agica Nacioanl de Vigilâcia Sanitáia (ANVISA), Acessed on November 2, 2011Markatseli, T.E., Papagoras, C., Drosos, A.A., Prognostic factors for erosive rheumatoid arthritis (2010) Clin Exp Rheumatol, 28 (1), pp. 114-123Visser, K., Goekoop-Ruiterman, Y.P., de Vries-Bouwstra, J.K., Ronday, H.K., Seys, P.E., Kerstens, P.J., A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: Post hoc analyses from the Be St study (2010) Ann Rheum Dis, 69 (7), pp. 1333-1337Smolen, J.S., Aletaha, D., Bijlsma, J.W., Breedveld, F.C., Boumpas, D., Burmester, G., Treating rheumatoid arthritis to target: Recommendations of an international task force (2010) Ann Rheum Dis, 69 (4), pp. 631-637Visser, K., Katchamart, W., Loza, E., Martinez-Lopez, J.A., Salliot, C., Trudeau, J., Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative (2009) Ann Rheum Dis, 68 (7), pp. 1086-1093Momohara, S., Inoue, E., Ikari, K., Yano, K., Tokita, A., Honjo, Y., Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute Mod Rheumatol, , 2011 Jul 15. [Epub ahead of print]Genovese, M.C., Cohen, S., Moreland, L., Lium, D., Robbins, S., Newmark, R., Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate (2004) Arthritis Rheum, 50 (5), pp. 1412-1419Weinblatt, M., Combe, B., Covucci, A., Aranda, R., Becker, J.C., Keystone, E., Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study (2006) Arthritis Rheum, 54 (9), pp. 2807-2816Kiely, P.D., Brown, A.K., Edwards, C.J., O'Reilly, D.T., Ostö, A.J., Quinn, M., Contemporary treatment principles for early rheumatoid arthritis: A consensus statement (2009) Rheumatology (Oxford), 48 (7), pp. 765-772Hochberg, M.C., Tracy, J.K., Hawkins-Holt, M., Flores, R.H., Comparison of the Efficacy of the tumour necrosis factor alphablocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis (2003) Ann Rheum Dis, 62 (SUPPL. 2), pp. 213-216Hetland, M.L., Christensen, I.J., Tarp, U., Dreyer, L., Hansen, A., Hansen, I.T., Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry (2010) Arthritis Rheum, 62 (1), pp. 22-32Goekoop-Ruiterman, Y.P., de Vries-Bouwstra, J.K., Allaart, C.F., van Zeben, D., Kerstens, P.J., Hazes, J.M., Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial (2005) Arthritis Rheum, 52 (11), pp. 3381-3390van der Kooij, S.M., le Cessie, S., Goekoop-Ruiterman, Y.P., de Vries-Bouwstra, J.K., van Zeben, D., Kerstens, P.J., Clinical and radiological Efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis (2009) Ann Rheum Dis, 68 (7), pp. 1153-1158Breedveld, F.C., Weisman, M.H., Kavanaugh, A.F., Cohen, S.B., Pavelka, K., van Vollenhoven, R., The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment (2006) Arthritis Rheum, 54 (1), pp. 26-37Emery, P., Genovese, M.C., van Vollenhoven, R., Sharp, J.T., Patra, K., Sasso, E.H., Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis (2009) J Rheumatol, 36 (7), pp. 1429-1441Emery, P., Breedveld, F., van der Heijde, D., Ferraccioli, G., Dougados, M., Robertson, D., Combination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial Group. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, doubleblind, randomized study (2010) Arthritis Rheum, 62 (3), pp. 674-682Kekow, J., Moots, R.J., Emery, P., Durez, P., Koenig, A., Singh, A., Patientreported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial (2010) Ann Rheum Dis, 69 (1), pp. 222-225Smolen, J.S., Han, C., van der Heijde, D.M., Emery, P., Bathon, J.M., Keystone, E., Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group (2009) Ann Rheum Dis, 68 (6), pp. 823-827. , Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: The impacts of remission and tumour necrosis factor blockadEmery, P., Fleischmann, R.M., Moreland, L.W., Hsia, E.C., Strusberg, I., Durez, P., Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twentyfour- week results of a phase III, multicenter, randomized, doubleblind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis (2009) Arthritis Rheum, 60 (8), pp. 2272-2283Strand, V., Mease, P., Burmester, G.R., Nika, E., Coteur, G., van Vollenhoven, R., Rapid and sustained improvements in health-related quality of life, fatigue, and other patientreported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: Results from the RAPID 1 randomized controlled trial (2009) Arthritis Res Ther, 11 (6), pp. R170Smolen, J., Landew, R.B., Mease, P., Brzezicki, J., Mason, D., Luijtens, K., Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study (2009) Ann Rheum Dis, 68 (6), pp. 797-804. , A randomized controlled trialvan Vollenhoven, R.F., Ernestam, S., Geborek, P., Petersson, I.F., Cöter, L., Waltbrand, E., Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial (2009) Lancet, 374 (9688), pp. 459-466Bejarano, V., Quinn, M., Conaghan, P.G., Reece, R., Keenan, A.M., Walker, D., Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis (2008) Arthritis Rheum, 59 (10), pp. 1467-1474Kimel, M., Cifaldi, M., Chen, N., Revicki, D., Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA (2008) J Rheumatol, 35 (2), pp. 206-215van Vollenhoven, R.F., Cifaldi, M.A., Ray, S., Chen, N., Weisman, M.H., Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: Work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study (2010) Arthritis Care Res (Hoboken), 62 (2), pp. 226-234Furst, D.E., Schiff, M.H., Fleischmann, R.M., Strand, V., Birbara, C.A., Compagnone, D., Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) (2003) J Rheumatol, 30 (12), pp. 2563-2571Nam, J.L., Winthrop, K.L., van Vollenhoven, R.F., Pavelka, K., Valesini, G., Hensor, E.M., Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of RA (2010) Ann Rheum Dis, 69 (6), pp. 976-986Kavanaugh, A., Smolen, J.S., Emery, P., Purcaru, O., Keystone, E., Richard, L., Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis (2009) Arthritis Rheum, 61 (11), pp. 1592-1600Genovese, M.C., Bathon, J.M., Martin, R.W., Fleischmann, R.M., Tesser, J.R., Schiff, M.H., Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes (2002) Arthritis Rheum, 46 (6), pp. 1443-1450Maini, R., Clair St., E.W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial (1999) Lancet, 354 (9194), pp. 1932-1939. , ATTRACT Study GroupKeystone, E., Genovese, M.C., Klareskog, L., Hsia, E.C., Hall, S., Miranda, P.C., Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GOFORWARD study (2010) Ann Rheum Dis, 69 (6), pp. 1129-1135Singh, J.A., Wells, G.A., Christensen, R., Tanjong, G.E., Maxwell, L., Macdonald, J.K., Adverse effects of biologics: A network meta-analysis and Cochrane overview (2011) Cochrane Database Syst Rev, 2. , CD008794Curtis, J.R., Patkar, N., Xie, A., Martin, C., Allison, J.J., Saag, M., Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists (2007) Arthritis Rheum, 56 (4), pp. 1125-1133Dixon, W.G., Symmons, D.P., Lunt, M., Watson, K.D., Hyrich, K.L., Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies (2007) Arthritis Rheum, 56 (9), pp. 2896-2904. , British Society for Rheumatology Biologics Register Control Centre Consortium et alRadstake, T.R., Svenson, M., Eijsbouts, A.M., van den Hoogen, F.H., Enevold, C., van Riel, P.L., Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis (2009) Ann Rheum Dis, 68 (11), pp. 1739-1745Bartelds, G.M., Wijbrandts, C.A., Nurmohamed, M.T., Stapel, S., Lems, W.F., Aarden, L., Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and antitumour necrosis factor naive patients: A cohort study (2010) Ann Rheum Dis, 69 (5), pp. 817-821Maxwell, L.J., Singh, J.A., Abatacept for rheumatoid arthritis: A Cochrane systematic review (2010) J Rheumatol, 37 (2), pp. 234-245Westhovens, R., Robles, M., Ximenes, A.C., Nayiager, S., Wollenhaupt, J., Durez, P., Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors (2009) Ann Rheum Dis, 68 (12), pp. 1870-1877Bathon, J., Robles, M., Ximenes, A.C., Nayiager, S., Wollenhaupt, J., Durez, P., Sustained disease remission and inhibition of radiographic progression in methotrexate-naïe patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes (2011) Ann Rheum Dis, 70 (11), pp. 1949-1956Miller, K.L., Sawitzke, A.D., Doane, J., Abatacept and serious respiratory infections in patients with previous lung disease (2008) Clin Rheumatol, 27 (12), pp. 1569-1571Cohen, S.B., Emery, P., Greenwald, M.W., Dougados, M., Furie, R.A., Genovese, M.C., Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary Efficacy and safety at twenty-four weeks (2006) Arthritis Rheum, 54 (9), pp. 2793-2806Emery, P., Deodhar, A., Rigby, W.F., Isaacs, J.D., Combe, B., Racewicz, A.J., Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) (2010) Ann Rheum Dis, 69 (9), pp. 1629-1635Keystone, E., Emery, P., Peterfy, C.G., Tak, P.P., Cohen, S., Genovese, M.C., Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies (2009) Ann Rheum Dis, 68 (2), pp. 216-221Popa, C., Leandro, M.J., Cambridge, G., Edwards, J.C., Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years (2007) Rheumatology (Oxford), 46 (4), pp. 626-630Chatzidionysiou, K., Lie, E., Nasonov, E., Lukina, G., Hetland, M.L., Tarp, U., Highest clinical effectiveness of rituximab in autoantibodypositive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: Pooled data from 10 European registries (2011) Ann Rheum Dis, 70 (9), pp. 1575-1580Jones, G., Sebba, A., Gu, J., Lowenstein, M.B., Calvo, A., Gomez-Reino, J.J., Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study (2010) Ann Rheum Dis, 69 (1), pp. 88-96Campbell, L., Chen, C., Bhagat, S.S., Parker, R.A., Östö, A.J., Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: A systematic literature review and meta-analysis of randomized controlled trials (2011) Rheumatology (Oxford), 50 (3), pp. 552-562Singh, J.A., Beg, S., Lopez-Olivo, M.A., Tocilizumab for rheumatoid arthritis: A Cochrane systematic review (2011) J Rheumatol, 38 (1), pp. 10-20Gout, T., Öandö, A.J., Nisar, M.K., Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: A systematic literature review (2011) Clin Rheumatol, 30 (11), pp. 1471-1474Suarez-Almazor, M.E., Spooner, C., Belseck, E., Azathioprine for treating rheumatoid arthritis (2000) Cochrane Database Syst Rev, (4). , CD001461Suarez-Almazor, M.E., Belseck, E., Shea, B., Wells, G., Tugwell, P., Cyclophosphamide for treating rheumatoid arthritis (2000) Cochrane Database Syst Rev, (4). , CD001157Wells, G., Haguenauer, D., Shea, B., Suarez-Almazor, M.E., Welch, V.A., Tugwell, P., Cyclosporine for rheumatoid arthritis (2000) Cochrane Database Syst Rev, (2). , CD001083Stein, C.M., Pincus, T., Yocum, D., Tugwell, P., Wells, G., Gluck, O., Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: An open-label extension study (1997) Arthritis Rheum, 40 (10), pp. 1843-1851. , The Methotrexate-Cyclosporine Combination Study GroupKnevel, R., Schoels, M., Huizinga, T.W., Aletaha, D., Burmester, G.R., Combe, B., Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis (2010) Ann Rheum Dis, 69 (6), pp. 987-994Katchamart, W., Trudeau, J., Phumethum, V., Bombardier, C., Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis (2010) Cochrane Database Syst Rev, 14 (4). , CD008495Scott, D.L., Wolfe, F., Huizinga, T.W., Rheumatoid arthritis (2010) Lancet, 376 (9746), pp. 1094-1108Suarez-Almazor, M.E., Belseck, E., Shea, B., Wells, G., Tugwell, P., Sulfasalazine for rheumatoid arthritis (2000) Cochrane Database Syst Rev, (2). , CD000958